Record Information |
---|
Version | 2.0 |
---|
Created at | 2006-08-10 09:50:09 UTC |
---|
Updated at | 2021-06-29 00:47:44 UTC |
---|
NP-MRD ID | NP0000724 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | Symmetric dimethylarginine |
---|
Description | Symmetric dimethylarginine, also known as N,n'-dimethylarginine or SDMA, is a L-arginine derivative having two methyl groups at the N(omega)- and N'(omega)-positions It has a role as an EC 1.14.13.39 (Nitric oxide synthase) inhibitor. It is a member of guanidines, a non-proteinogenic L-alpha-amino acid, a L-arginine derivative and a dimethylarginine. It is a tautomer of a N(omega),N'(omega)-dimethyl-L-arginine zwitterion. It belongs to the class of organic compounds known as arginine and derivatives. Arginine and derivatives are compounds containing arginine or a derivative thereof resulting from reaction of arginine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. Symmetric dimethylarginine is a drug. Outside of the human body, symmetric dimethylarginine has been detected, but not quantified in pulses. Symmetric dimethylarginine (SDMA) is an endogenously produced inhibitor of nitric oxide synthase (EC-Number 1.14.13.39). However, elevated levels of Symmetric dimethylarginine occur in patients with vascular disease, especially suffering end-stage renal disease. |
---|
Structure | CN\C(NCCC[C@H](N)C(O)=O)=N/C InChI=1S/C8H18N4O2/c1-10-8(11-2)12-5-3-4-6(9)7(13)14/h6H,3-5,9H2,1-2H3,(H,13,14)(H2,10,11,12)/t6-/m0/s1 |
---|
Synonyms | Value | Source |
---|
(2S)-2-Amino-5-(n',n''-dimethylcarbamimidamido)pentanoic acid | ChEBI | (S)-2-Amino-5-(n',n''-dimethylguanidino)pentanoic acid | ChEBI | Guanidino-N(1),N(2)-dimethylarginine | ChEBI | N(g1),N(g2)-Dimethylarginine | ChEBI | N,N'-dimethylarginine | ChEBI | N(3),N(4)-Dimethyl-L-arginine | ChEBI | N(3),N(4)-Dimethylarginine | ChEBI | N5-((Methylamino)(methylimino)methyl)-L-ornithine | ChEBI | N(5)-(N,N'-dimethylamidino)-L-ornithine | ChEBI | N(5)-(N,N'-dimethylcarbamimidoyl)-L-ornithine | ChEBI | N(5)-[Bis(methylamino)methylene]-L-ornithine | ChEBI | N(g),N'(g)-dimethyl-L-arginine | ChEBI | N(g),N'(g)-dimethylarginine | ChEBI | SDMA | ChEBI | (2S)-2-Amino-5-(n',n''-dimethylcarbamimidamido)pentanoate | Generator | (S)-2-Amino-5-(n',n''-dimethylguanidino)pentanoate | Generator | N5-(N,N'-dimethylamidino)-L-ornithine | HMDB | N5-[Bis(methylamino)methylene]-L-ornithine | HMDB | NG,N'G-dimethyl-L-arginine | HMDB | NG,N'G-dimethylarginine | HMDB | NG,NG'-dimethylarginine | HMDB | Omega-N(g),n'(g)-dimethylarginine | HMDB | SDMA arginine | HMDB |
|
---|
Chemical Formula | C8H18N4O2 |
---|
Average Mass | 202.2541 Da |
---|
Monoisotopic Mass | 202.14298 Da |
---|
IUPAC Name | (2S)-2-amino-5-[(E)-N',N''-dimethylcarbamimidamido]pentanoic acid |
---|
Traditional Name | N3, N4-dimethylarginine |
---|
CAS Registry Number | 30344-00-4 |
---|
SMILES | CN\C(NCCC[C@H](N)C(O)=O)=N/C |
---|
InChI Identifier | InChI=1S/C8H18N4O2/c1-10-8(11-2)12-5-3-4-6(9)7(13)14/h6H,3-5,9H2,1-2H3,(H,13,14)(H2,10,11,12)/t6-/m0/s1 |
---|
InChI Key | HVPFXCBJHIIJGS-LURJTMIESA-N |
---|
Experimental Spectra |
---|
|
| Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Predicted Spectra |
---|
|
| Not Available | Chemical Shift Submissions |
---|
|
| Not Available | Species |
---|
Species of Origin | |
---|
Species Where Detected | |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as arginine and derivatives. Arginine and derivatives are compounds containing arginine or a derivative thereof resulting from reaction of arginine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Amino acids, peptides, and analogues |
---|
Direct Parent | Arginine and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Arginine or derivatives
- Alpha-amino acid
- L-alpha-amino acid
- Fatty acid
- Guanidine
- Amino acid
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Carboximidamide
- Propargyl-type 1,3-dipolar organic compound
- Organic 1,3-dipolar compound
- Amine
- Primary amine
- Organooxygen compound
- Organonitrogen compound
- Organic nitrogen compound
- Primary aliphatic amine
- Imine
- Organic oxygen compound
- Carbonyl group
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Aliphatic acyclic compound
|
---|
Molecular Framework | Aliphatic acyclic compounds |
---|
External Descriptors | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Predicted Properties | |
---|
General References | - Wang J, Sim AS, Wang XL, Salonikas C, Naidoo D, Wilcken DE: Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis. 2006 Feb;184(2):383-8. Epub 2005 Jun 6. [PubMed:15939423 ]
- Fleck C, Schweitzer F, Karge E, Busch M, Stein G: Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clin Chim Acta. 2003 Oct;336(1-2):1-12. [PubMed:14500028 ]
- Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP: Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998 Nov 3;98(18):1842-7. [PubMed:9799202 ]
- Nijveldt RJ, Van Leeuwen PA, Van Guldener C, Stehouwer CD, Rauwerda JA, Teerlink T: Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol Dial Transplant. 2002 Nov;17(11):1999-2002. [PubMed:12401860 ]
- Schiel R, Franke S, Busch M, Muller A, Fleck C, Muller UA, Braun A, Stein G: Effect of smoking on risk factors for cardiovascular disease in patients with diabetes mellitus and renal insufficiency. Eur J Med Res. 2003 Jul 31;8(7):283-91. [PubMed:12911864 ]
- Mittermayer F, Pleiner J, Krzyzanowska K, Wiesinger GF, Francesconi M, Wolzt M: Regular physical exercise normalizes elevated asymmetrical dimethylarginine concentrations in patients with type 1 diabetes mellitus. Wien Klin Wochenschr. 2005 Dec;117(23-24):816-20. [PubMed:16437318 ]
- Krzyzanowska K, Mittermayer F, Schnack C, Hofer M, Wolzt M, Schernthaner G: Circulating ADMA concentrations are elevated in hypopituitary adults with and without growth hormone deficiency. Eur J Clin Invest. 2005 Mar;35(3):208-13. [PubMed:15733076 ]
- Marliss EB, Chevalier S, Gougeon R, Morais JA, Lamarche M, Adegoke OA, Wu G: Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia. 2006 Feb;49(2):351-9. Epub 2005 Dec 21. [PubMed:16369774 ]
- Schmidt RJ, Baylis C: Total nitric oxide production is low in patients with chronic renal disease. Kidney Int. 2000 Sep;58(3):1261-6. [PubMed:10972689 ]
- Ellis J, Wennerholm UB, Bengtsson A, Lilja H, Pettersson A, Sultan B, Wennergren M, Hagberg H: Levels of dimethylarginines and cytokines in mild and severe preeclampsia. Acta Obstet Gynecol Scand. 2001 Jul;80(7):602-8. [PubMed:11437716 ]
- Teerlink T, Neele SJ, de Jong S, Netelenbos JC, Stehouwer CD: Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin Sci (Lond). 2003 Jul;105(1):67-71. [PubMed:12625833 ]
- Mittermayer F, Namiranian K, Pleiner J, Schaller G, Wolzt M: Acute Escherichia coli endotoxaemia decreases the plasma l-arginine/asymmetrical dimethylarginine ratio in humans. Clin Sci (Lond). 2004 Jun;106(6):577-81. [PubMed:14741043 ]
|
---|